PressJuly 13, 2022 Albert Labs Files US Provisional Patent Application for Psilocybe And Other Mycelia
PressJuly 12, 2022 Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study
PressJuly 8, 2022 Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
PressJuly 7, 2022 Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
PressJuly 6, 2022 CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
PressJuly 5, 2022 Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
PressJuly 1, 2022 atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
PressJune 28, 2022 Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
PressJune 22, 2022 Numinus Applies for International Patent Filing of Psychedelics Production Process
PressJune 21, 2022 Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation
PressJune 17, 2022 U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
PressJune 16, 2022 Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
PressJune 15, 2022 Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders
PressJune 14, 2022 Filament Health Cultivates 70th Variety of Psilocybin-containing Mushrooms At Vancouver Facility
